# Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

> **NCT05401110** · PHASE1 · RECRUITING · sponsor: **Karen Reckamp, MD, MS** · enrollment: 60 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Carotuximab

## Key facts

- **NCT ID:** NCT05401110
- **Lead sponsor:** Karen Reckamp, MD, MS
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-15
- **Primary completion:** 2028-01
- **Final completion:** 2029-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05401110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05401110, "Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05401110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*